The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

milestonepharma.com

Founded Year

2003

Stage

IPO | IPO

Total Raised

$165M

Date of IPO

5/9/2019

Market Cap

0.17B

Stock Price

5.57

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur.

Milestone Pharmaceuticals Headquarter Location

1111 Dr.-Frederik-Philips Blvd Suite 420

Saint-Laurent, Quebec, H4M 2X6,

Canada

514-336-0444

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Milestone Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Milestone Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Milestone Pharmaceuticals Patents

Milestone Pharmaceuticals has filed 18 patents.

The 3 most popular patent topics include:

  • Calcium channel blockers
  • Cardiac arrhythmia
  • Cardiac anatomy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/18/2017

7/3/2018

Cardiac arrhythmia, Calcium channel blockers, Heart diseases, Acetylcholinesterase inhibitors, Cardiac anatomy

Grant

Application Date

7/18/2017

Grant Date

7/3/2018

Title

Related Topics

Cardiac arrhythmia, Calcium channel blockers, Heart diseases, Acetylcholinesterase inhibitors, Cardiac anatomy

Status

Grant

Latest Milestone Pharmaceuticals News

07:00 EDT Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022

News provided by Share this article Share this article MONTREAL and CHARLOTTE, N.C., May 17, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022. The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com . An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit  www.milestonepharma.com  and follow Milestone on Twitter at @MilestonePharma. Contact

Milestone Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Milestone Pharmaceuticals Rank

  • When was Milestone Pharmaceuticals founded?

    Milestone Pharmaceuticals was founded in 2003.

  • Where is Milestone Pharmaceuticals's headquarters?

    Milestone Pharmaceuticals's headquarters is located at 1111 Dr.-Frederik-Philips Blvd, Saint-Laurent.

  • What is Milestone Pharmaceuticals's latest funding round?

    Milestone Pharmaceuticals's latest funding round is IPO.

  • How much did Milestone Pharmaceuticals raise?

    Milestone Pharmaceuticals raised a total of $165M.

  • Who are Milestone Pharmaceuticals's competitors?

    Competitors of Milestone Pharmaceuticals include Flexion Therapeutics, Presage Biosciences, Ra Pharmaceuticals, WaferGen Bio-systems, Allozyne and 13 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Q
QPS

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

O
Optimata

Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.

Presage Biosciences Logo
Presage Biosciences

Presage Biosciences is an oncology company that focuses on evaluating patient response to drugs in clinical trials. The company uses CIVO technology to deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

I
IEP

IEP develops biocatalytic (enzymatic) processes for the manufacture of high-value chemicals or pharmaceutical intermediates that reduce cost, time, amounts of toxic solvents used and unwanted side products when compared to traditional chemistry. The company currently has 13 industrial processes in commercial operation and offers routes of synthesis to more than 50 products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.